Rodent models of pulmonary hypertension: harmonisation with the world health organisation’s categorisation of human PH

Abstract

The WHO classification of pulmonary hypertension (PH) recognises five distinct groups, all sharing a mean, resting, pulmonary artery pressure (PAP) > 25 mmHg. The aetiology of PH varies by group (1-pulmonary vascular disease, 2-high left heart filling pressures, 3-hypoxia, 4-unresolved pulmonary embolism and 5-miscellaneous). Inclusion in a group reflects shared histological, haemodynamic and pathophysiological features and has therapeutic implications. Advantages of using rodent models to understand the pathophysiology of human PH and to test experimental therapies include the economy, safety and mechanistic certainty they provide. As rodent models are meant to reflect human PH, they should be categorised by a parallel PH classification and limitations in achieving this ideal recognised. Challenges with rodent models include: accurate phenotypic characterisation (haemodynamics, histology and imaging), species and strain variations in the natural history of PH, and poor fidelity to the relevant human PH group. Rat models of group 1 PH include: monocrotaline (± pneumonectomy), chronic hypoxia + SU-5416 (a VEGF receptor inhibitor) and the fawn-hooded rat (FHR). Mouse models of group 1 PH include: transgenic mice overexpressing the serotonin transporter or dominant-negative mutants of bone morphogenetic protein receptor-2. Group 1 PH is also created by infecting S100A4/Mts1 mice with γ-herpesvirus. The histological features of group 1 PH, but not PH itself, are induced by exposure to Schistosoma mansoni or Stachybotrys chartarum. Group 3 PH is modelled by exposure of rats or mice to chronic hypoxia. Rodent models of groups 2, 4 and 5 PH are needed. Comprehensive haemodynamic, histological and molecular phenotyping, coupled with categorisation into WHO PH groups, enhances the utility of rodent models.

What people with Down Syndrome can teach us about cardiopulmonary disease

“…Pulmonary vascular diseases are wide-ranging in their aetiology and pathogenesis. Pulmonary embolism and pulmonary oedema are commonly found on computed tomography in pulmonary vascular diseases such as CHD, altitude sickness and pulmonary artery hypertension (PAH) [42][43][44][45][46]. Embolism and oedema in the lung secondary to left heart disease are thought to derive from changes in endothelial permeability and are probably related to potassium and calcium channel disturbances [47][48][49].…”

Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future

“…There has been much criticism of animal models of PAH and it is true that none truly recapitulate the human condition (Ryan, Bloch, & Archer, 2011;Stenmark, Meyrick, Galie, Mooi, & McMurtry, 2009). To compensate for this, investigators are often asked to provide evidence of a beneficial effect in more than one animal model but, as is evident with statins, this still has serious limitations as a predictor of response in patients.…”

The Sugen 5416/Hypoxia Mouse Model of Pulmonary Hypertension Revisited: Long‐Term Follow‐Up

“…11 Lung tissue perfusion and histology Under isoflurane anesthesia, the chest was opened and the pulmonary vasculature was perfused with phosphatebuffered saline through the beating RV. The heart and lungs were removed en bloc, and the lungs were inflated ex vivo with 4% neutral buffered formalin at a fixed pressure of 20 cm of H 2 O.…”